# EDGAR Filing Document

**Accession Number:** 0001849296
**File Stem:** 0001493152-23-000165
**Filing Date:** 2023-1
**Character Count:** 2694
**Document Hash:** c3c3300900a41a64a81c5ac83db6a30b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-000165.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001493152-23-000165

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OKYO Pharma Ltd
- **CENTRAL INDEX KEY:** 0001849296
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA
- **BUSINESS PHONE:** 44 (0) 207 495 2379

**MAIL ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA

January 3, 2023

**<u>Via EDGAR</u>**

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

Attn: Tyler Howes

---

| | |
|:---|:---|
| **Re:** | **OKYO Pharma LTD (the "Company")** |
|  | **Registration Statement on Form F-1/A** |
|  | **File No. 333-268675** |
|  | **Acceleration Request** |

---

---

| |
|:---|
| **Requested Date: January 5, 2023** |
| **Requested Time: 5:00 p.m., Eastern Standard Time** |

---

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "***Act***"), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the "***Commission***") take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the "***Registration Statement***") to become effective on Thursday, January 5, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

*[Signature Page Follows]*

Securities and Exchange Commission, p. 2

January 3, 2023

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| ThinkEquity LLC | ThinkEquity LLC |
| By: | */s/ Priynaka Mahajan* |
| Name: | Priyanka Mahajan |
| Title: | Managing Director, Investment Banking |

---

cc: Gary Jacob, OKYO Pharma Ltd <br> Jeffrey Fessler, Sheppard, Mullin, Richter & Hampton LLP <br> Anthony Marsico, Dorsey & Whitney LLP